Company will introduce new cPET™ solution for automated FDG and amyloid PET quantification to its platform to go beyond neurological image quantification
New cPET application
New cARIA application
New cMRI clinically focused reports and unique Dementia Differential Analysis report
Additional recent news
Hausmann will be presenting “MRI Only Differentiation of Dementias: AI-enabled Diagnostic Trend to Enable Differentiation of Dementias with Imaging Alone” on November 28 in the AI Theatre at RSNA. Combinostics’ leadership and sales team will also be demoing the newest capabilities of their solutions, including the new reports and cPET, which will be available for clinical use in the United States in early 2023, at booth 3938 in the AI Showcase. Schedule an in-person or virtual meeting.
Combinostics’ AI-powered cNeuro suite of products helps clinicians make a difference in the lives of patients with neurological disorders. By quantifying brain images and integrating patient data from multiple sources with insights from previous patients, the company’s unique software tools provide radiologists and clinicians the support they need for confident, evidence-based diagnostic and management decisions. The company was founded in 2014 and is headquartered in Tampere, Finland. For more information, please visit www.combinostics.com.